106 related articles for article (PubMed ID: 7184381)
21. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation.
Björkstrand B; Ljungman P; Bird JM; Samson D; Brandt L; Alegre A; Auzanneau G; Bladé J; Brunet S; Carlson K
Stem Cells; 1995 Aug; 13 Suppl 2():140-6. PubMed ID: 8520503
[TBL] [Abstract][Full Text] [Related]
22. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Poser M; Müller S; Flasshove M; Moritz T; Seeber S; Nowrousian MR
Ann Hematol; 2005 Sep; 84(9):594-600. PubMed ID: 15744524
[TBL] [Abstract][Full Text] [Related]
23. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
24. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
25. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
26. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease.
Hungria VT; Latrilha MC; Rodrigues DG; Bydlowski SP; Chiattone CS; Maranhão RC
Cancer Chemother Pharmacol; 2004 Jan; 53(1):51-60. PubMed ID: 14574458
[TBL] [Abstract][Full Text] [Related]
27. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide and dexamethasone: therapy for multiple myeloma.
Kumar S; Rajkumar SV
Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports.
Cavo M; Benni M; Cirio TM; Gozzetti A; Tura S
Stem Cells; 1995 Aug; 13 Suppl 2():126-31. PubMed ID: 8520501
[TBL] [Abstract][Full Text] [Related]
30. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
31. Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.
Alberts DS; Durie BG; Salmon SE
Cancer Treat Rep; 1977; 61(3):381-8. PubMed ID: 872138
[TBL] [Abstract][Full Text] [Related]
32. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
33. Severe combined immunodeficiency (SCID) mouse modeling of P-glycoprotein chemosensitization in multidrug-resistant human myeloma xenografts.
Bellamy WT; Odeleye A; Huizenga E; Dalton WS; Weinstein RS; Grogan TM
Clin Cancer Res; 1995 Dec; 1(12):1563-70. PubMed ID: 9815957
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
35. A new basis for treatment of multiple myeloma.
Salmon SE; Durie BG; Hamburger AW
Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma: a therapeutic enigma.
Hoogstraten B
Am J Clin Oncol; 1982 Feb; 5(1):13-9. PubMed ID: 7081135
[TBL] [Abstract][Full Text] [Related]
37. [Determination of the tumor cell mass and its significance as a parameter for prognosis and therapy in patients with multiple myeloma].
Ludwig H; Schneider K; Pietschmann H
Acta Med Austriaca; 1978; 5(4-5):164-6. PubMed ID: 756132
[TBL] [Abstract][Full Text] [Related]
38. Hemibody irradiation in stage III multiple myeloma: results of 20 patients.
Troussard X; Roussel A; Reman O; Macro M; Leporrier M
Nouv Rev Fr Hematol (1978); 1988; 30(4):213-8. PubMed ID: 3057435
[TBL] [Abstract][Full Text] [Related]
39. [Treatment of multiple myeloma].
Clément F
Schweiz Med Wochenschr; 1986 Feb; 116(8):230-9. PubMed ID: 3082003
[TBL] [Abstract][Full Text] [Related]
40. [Our experience with the treatment of multiple myeloma and its complications].
Abdulkadyrov KM; Ushakova EA
Probl Gematol Pereliv Krovi; 1979 Dec; 24(12):35-40. PubMed ID: 523449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]